Search Results

CSL Seqirus, a business of CSL, was selected by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to complete the fill and finish process of pre-pandemic vaccine for the U.S. government as part of the National Pre-Pandemic Influenza Vaccine Stockpile program.

CSL Seqirus commends the National Advisory Committee on Immunization’s recent recommendation for adults 65 years of age and older to preferentially receive an enhanced influenza vaccine, which includes adjuvanted, high-dose and recombinant vaccines.

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee.

CSL Seqirus, a global leader in influenza prevention, announced the presentation of data from two Canadian studies at the 2023 Canadian Immunization Conference in Ottawa, Ontario.